Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19134426 | 1.00 | GRIN2B (0.48) | GRIN2BGRIN2CCTSLCTSKCTSB | |
| SCHEMBL19129086 | 1.00 | GRIN2B (0.48) | GRIN2BGRIN2CCTSLCTSKCTSB | |
| SCHEMBL15937106 | 1.00 | GRIN2B (0.48) | GRIN2BGRIN2CCTSLCTSKCTSB | |
| SCHEMBL19134413 | 0.89 | GRIN2B (0.61) | GRIN2BGRIN2CTSHR | |
| SCHEMBL17359174 | 0.89 | GRIN2B (0.61) | GRIN2BGRIN2CTSHR | |
| SCHEMBL17351873 | 0.89 | GRIN2B (0.61) | GRIN2BGRIN2CTSHR | |
| SCHEMBL15937099 | 0.86 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL17359175 | 0.86 | GRIN2B (0.41) | GRIN2BGRIN2C | |
| SCHEMBL15937149 | 0.84 | GRIN2B (0.40) | GRIN2BGRIN2C | |
| SCHEMBL15937078 | 0.84 | GRIN2B (0.40) | GRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885CTSL 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.